ALVAL — Valbiotis SA Share News
0.000.00%
Last trade - 00:00- €18.60m
- €11.17m
- €0.91m
Brief: Valbiotis Announces Valedia Key Data
Brief: Valbiotis Launches Capital Increase By Private Placement For Maximum Of 20 Percent Of Capital
Brief: Valbiotis Reports H1 Operating Loss Of 1.9 Million Euros
Brief: Valbiotis Announces Positive Results From Its Phase I/II Clinical Study On LpD64
Brief: Valbiotis Announces Positive Results For Val-070 In Hypercholesterolemia
Brief: Valbiotis Initiates The Clinical Development Of Valediatm In The United-States With The Reverse-It Clinical Study
Brief: Valbiotis Appoints Christine Roy-Duval As Director Of Development And Medical Affairs
Brief: Valbiotis Obtains Patent For Valedia® In United States
Brief: Valbiotis Completes Phase I/II Clinical Study Recruitment For VAL-070
Brief: Valbiotis Announces Significant Effect Of Valedia On Intestinal Microbiota
Brief: Valbiotis Announces Positive Preclinical Results For Totum-63
Brief: Valbiotis Announces First Preclinical Data On Metformin + Totum-63 Combination For Diabetes
Brief: Valbiotis launches "pivotal" REVERSE-IT clinical trial of VALEDIA
Brief: Valbiotis confirms efficacy of Lipidrive in three models and finalizes recruitment for phase I/II
Brief: Valbiotis H1 operating loss widens to 0.3 million euros
Brief: Valbiotis appoints Pascal Sirvent director of Discovery and Preclinical Research
Brief: Valbiotis announces exercise of overallotment option in IPO
Brief: Valbiotis says Phase I/II Valedia study validate safety and first proof of efficacy